JX
JXFGF.US Jinxin Fertility Group Limited
- Market cap
- USD 720M
- P/E
- -
- P/B
- 0.55x
- ROE
- 4.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is JXFGF.US undervalued?
Graham numberThe Graham number of Jinxin Fertility Group Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jinxin Fertility Group Limited fundamental analysis
No fundamental analysis for Jinxin Fertility Group Limited yet.
Jinxin Fertility Group Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jinxin Fertility Group Limited
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and internationally. The company provides two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also related services, such a…
Full company profileJinxin Fertility Group Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jinxin Fertility Group Limited annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 346M | 663M | 922M | 1.65B | 1.43B | 1.84B | 2.36B | 2.79B | 2.81B | 2.58B | 5.42B |
| Gross Profit | 133M | 302M | 413M | 817M | 566M | 771M | 913M | 1.18B | 1.10B | 818M | 1.93B |
| Operating Income | 127M | 231M | 277M | 530M | 238M | 371M | 285M | 480M | 454M | 198M | 775M |
| EBITDA | 141M | 267M | 319M | 643M | 371M | 541M | 545M | 765M | 726M | 542M | 1.45B |
| Net Income | 87.6M | 98.8M | 167M | 410M | 252M | 340M | 121M | 345M | 283M | -951M | 424M |
| EPS | 0.04 | 0.04 | 0.07 | 0.19 | 0.10 | 0.14 | 0.05 | 0.13 | 0.10 | -0.35 | 0.16 |
| Balance Sheet | |||||||||||
| Total Assets | 755M | 1.74B | 6.56B | 8.94B | 9.16B | 12.8B | 15.2B | 14.9B | 15.0B | 14.0B | 13.8B |
| Total Liabilities | 655M | 376M | 2.06B | 1.30B | 1.70B | 4.07B | 6.50B | 4.71B | 4.63B | 4.77B | 4.86B |
| Shareholders' Equity | 79.2M | 928M | 4.36B | 7.53B | 7.28B | 8.55B | 8.64B | 10.1B | 10.3B | 9.15B | 8.91B |
| Cash & Short-term Investments | 191M | 449M | 1.27B | 3.30B | 2.47B | 1.93B | 1.40B | 853M | 571M | 906M | 805M |
| Total Debt | - | - | - | 183M | 407M | 2.09B | 4.16B | 2.55B | 2.60B | 2.96B | 3.00B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 109M | 47.7M | 356M | 453M | 308M | 343M | 542M | 684M | 629M | 476M | 812M |
| Capital Expenditure | 8.01M | 32.2M | 21.0M | 277M | 266M | 79.8M | 959M | 174M | 262M | 258M | 406M |
| Free Cash Flow | 101M | 15.5M | 335M | 175M | 41.9M | 264M | -418M | 511M | 367M | 218M | 406M |
| Ratios | |||||||||||
| ROE | 110.6% | 10.6% | 3.8% | 5.4% | 3.5% | 4.0% | 1.4% | 3.4% | 2.8% | -10.4% | 4.8% |
| ROA | 11.6% | 5.7% | 2.5% | 4.6% | 2.7% | 2.7% | 0.8% | 2.3% | 1.9% | -6.8% | 3.1% |
| Net Profit Margin | 25.3% | 14.9% | 18.1% | 24.8% | 17.6% | 18.5% | 5.1% | 12.4% | 10.1% | -36.8% | 7.8% |
| Debt to Equity | - | - | - | 0.02x | 0.06x | 0.24x | 0.48x | 0.25x | 0.25x | 0.32x | 0.34x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jinxin Fertility Group Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | CNY 150M | 0.06 | 53.0% |
| 2023 | CNY 10.5M | 0.00 | 3.0% |
| 2022 | CNY 159M | 0.06 | 131.0% |
| 2021 | USD 66.7M | 0.03 | 19.6% |
| 2020 | USD 150M | 0.06 | 59.5% |
| 2019 | USD 328M | 0.15 | 80.0% |
| 2018 | USD 124M | 0.05 | 74.4% |
| 2017 | USD 60.2M | 0.03 | 60.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Jinxin Fertility Group Limited
- Insiders 13.32%
- Institutions 14.78%
- Public & others 71.90%
- Shares outstanding 2.48B
- Free float 2.13B
Jinxin Fertility Group Limited company profile
- Company name
- Jinxin Fertility Group Limited
- Ticker
- JXFGF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 3,128
- Fiscal year end
- December
- Address
- No. 301, North Jingsha Road, Chengdu, China
- Phone
- 86 28 6769 5992
- Website
- jxr-fertility.com
About Jinxin Fertility Group Limited
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and internationally. The company provides two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; obstetrics, gynecology, urology, internal medicine, and pediatrics medical services; ambulatory surgery center facilities services; and ancillary medical services. Further, it provides pre-implantation genetic screening testing, management consultancy, postpartum and rehabilitation care, maternal-child nursing, and other hospital- derived services. Additionally, the company is involved in property investment, and real estate development and operation activities; sale of medicines, consumables, and equipment; research and development of IVF related projects, including scientific research and related commercialization; and operates restaurant. Jinxin Fertility Group Limited was founded in 1951 and is headquartered in Chengdu, China.
Jinxin Fertility Group Limited management
6- Mr. Yang DongCEO, Acting CFO & Executive Director · born 1987
- Dr. Rong LyuCo-CEO & Executive Director · born 1982
- Ms. Hongmei DuanChief Operating Officer · born 1982
- Dr. Lihong GengChief Medical Quality Control Officer & Executive Director · born 1969
- Dr. Yuan LiChief Medical Officer · born 1972
- Ms. Man Nar ChungCompany Secretary